Galecto raise US$85m in Nasdaq IPO
HBM portfolio company Galecto has raised US$85m through the placement of 5.67 million new shares at a price of US$15 per share at Nasdaq.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1306 entries already.
Entries by Thomas Gabrielczyk
BI initiates Phase II testing of COVID-19 drug
/in News/by Thomas GabrielczykBoehringer Ingelheim announced the start of Phase II studies of its oral TRPC6 blocker code-named BI 764198 in patients hospitalised for COVID-19.
3P Bio to manufacture SpyBiotech vaccine
/in News/by Thomas GabrielczykBritish SpyBiotech has outsourced GMP manufacturing of its VLP vaccine platform to Navarra-based 3P Biopharmaceuticals.
Bioinvent AB licences BI-1206 to CASI Pharmaceuticals
/in News/by Thomas GabrielczykSwedish BioInvent AB has licensed its anti-Fc?RllB antibody BI-1206 for $95m to CASI Pharmaceuticals for distribtion in the Greater China region
Transgene reports clinical results of TG4001 plus avelumab
/in News/by Thomas GabrielczykTransgene SA has reported positive results of an exploratory Phase Ib/II study in HPV-16-positive cancers combining its cancer vaccine TG4001 with Merck KgaAs PD-L1 blocker avelumab.
Roche licences antiviral nucleoside from Atea
/in News/by Thomas GabrielczykRoche AG has paid US$350 in cash to co.develop and market Atea Pharmaceuticals oral direct-acting antiviral, AT-527, to limit proliferation of SARS-CoV-2.
ADC company Araris Biotech raises CHF15.2m
/in News/by Thomas GabrielczykNew ADC company Araris Biotech has got backing by Pureos Bioventures and co-investors in a CHF15.2m seed round to develop a new class of antibody drug conjugates. ·
Vifor Pharma in US$100m licence deal with Cara Therapeutics
/in News/by Thomas GabrielczykVifor Pharma and Cara Therapeutics have signed a US license agreement for Korsuva to treat dialysis patients with pruritus.
Atriva Therapeutics gets 24m from EIB
/in News/by Thomas GabrielczykAtriva Therapeutics has secured a 24m loan to push the development of its COVID-19 programme ATR-002, an antiviral, anti-inflammatory MEK inhibitor.
Topas raises 22m in Series B financining
/in News/by Thomas GabrielczykTopas Therapeutics GmbH will use the 22m proceeds from a Series B Financing to advance two pipeline candidates.